Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 2
1951 4
1952 4
1953 4
1954 5
1955 3
1956 4
1958 2
1959 5
1960 3
1961 4
1962 12
1963 12
1964 17
1965 14
1966 21
1967 24
1968 21
1969 33
1970 32
1971 28
1972 22
1973 21
1974 25
1975 40
1976 25
1977 35
1978 53
1979 46
1980 53
1981 69
1982 50
1983 59
1984 53
1985 72
1986 79
1987 81
1988 89
1989 122
1990 123
1991 102
1992 108
1993 130
1994 121
1995 119
1996 120
1997 132
1998 154
1999 117
2000 128
2001 133
2002 148
2003 115
2004 161
2005 139
2006 146
2007 175
2008 156
2009 173
2010 174
2011 205
2012 216
2013 206
2014 235
2015 249
2016 258
2017 307
2018 259
2019 279
2020 391
2021 463
2022 425
2023 76
Text availability
Article attribute
Article type
Publication date

Search Results

7,018 results
Results by year
Filters applied: . Clear all
Page 1
Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis.
Laukhtina E, Shim SR, Mori K, D'Andrea D, Soria F, Rajwa P, Mostafaei H, Compérat E, Cimadamore A, Moschini M, Teoh JY, Enikeev D, Xylinas E, Lotan Y, Palou J, Gontero P, Babjuk M, Witjes JA, Kamat AM, Roupret M, Shariat SF, Pradere B; European Association of Urology–Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Laukhtina E, et al. Among authors: mori k. Eur Urol Oncol. 2021 Dec;4(6):927-942. doi: 10.1016/j.euo.2021.10.003. Epub 2021 Nov 6. Eur Urol Oncol. 2021. PMID: 34753702 Free article. Review.
Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.
Uchimoto T, Fukushima T, Komura K, Fukuokaya W, Adachi T, Hashimoto T, Yoshizawa A, Nakamura K, Yano Y, Nishimura K, Nishio K, Nakamori K, Iwatani K, Yamamoto S, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Kimura T, Ohno Y, Shiroki R, Egawa S, Azuma H. Uchimoto T, et al. Among authors: mori k. BJU Int. 2022 Sep 13. doi: 10.1111/bju.15893. Online ahead of print. BJU Int. 2022. PMID: 36098556
Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
Yanagisawa T, Rajwa P, Thibault C, Gandaglia G, Mori K, Kawada T, Fukuokaya W, Shim SR, Mostafaei H, Motlagh RS, Quhal F, Laukhtina E, Pallauf M, Pradere B, Kimura T, Egawa S, Shariat SF. Yanagisawa T, et al. Among authors: mori k. Eur Urol. 2022 Dec;82(6):584-598. doi: 10.1016/j.eururo.2022.08.002. Epub 2022 Aug 19. Eur Urol. 2022. PMID: 35995644 Free article. Review.
Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study.
Kenmotsu H, Wakuda K, Mori K, Kato T, Sugawara S, Kirita K, Yoneshima Y, Azuma K, Nishino K, Teraoka S, Shukuya T, Masuda K, Hayashi H, Toyozawa R, Miura S, Fujimoto D, Nakagawa K, Yamamoto N, Takahashi T. Kenmotsu H, et al. Among authors: mori k. J Thorac Oncol. 2022 Sep;17(9):1098-1108. doi: 10.1016/j.jtho.2022.05.006. Epub 2022 May 27. J Thorac Oncol. 2022. PMID: 35636696 Free article. Clinical Trial.
Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes.
Laukhtina E, Sari Motlagh R, Mori K, Katayama S, Rajwa P, Yanagisawa T, Quhal F, Mostafaei H, Grossmann NC, König F, Aydh A, Pradere B, Resch I, Merseburger AS, Enikeev D, Shariat SF. Laukhtina E, et al. Among authors: mori k. Crit Rev Oncol Hematol. 2022 Jan;169:103570. doi: 10.1016/j.critrevonc.2021.103570. Epub 2021 Dec 10. Crit Rev Oncol Hematol. 2022. PMID: 34902554 Free article. Review.
Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis.
Rajwa P, Pradere B, Gandaglia G, van den Bergh RCN, Tsaur I, Shim SR, Yanagisawa T, Laukhtina E, Mori K, Mostafaei H, Quhal F, Bryniarski P, Compérat E, Roubaud G, Massard C, Merseburger AS, Leapman MS, Spratt DE, Saad F, Joniau S, D'Amico AV, Briganti A, Shariat SF, Ploussard G; European Association of Urology Young Academic Urologists Prostate Cancer Working Party. Rajwa P, et al. Among authors: mori k. Eur Urol. 2022 Jul;82(1):82-96. doi: 10.1016/j.eururo.2022.03.031. Epub 2022 Apr 22. Eur Urol. 2022. PMID: 35465985 Free article. Review.
The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: A systematic review and meta-analysis.
Mori K, Quhal F, Yanagisawa T, Katayama S, Pradere B, Laukhtina E, Rajwa P, Mostafaei H, Sari Motlagh R, Kimura T, Egawa S, Bensalah K, Karakiewicz PI, Schmidinger M, Shariat SF. Mori K, et al. Int Immunopharmacol. 2022 Jul;108:108720. doi: 10.1016/j.intimp.2022.108720. Epub 2022 Mar 24. Int Immunopharmacol. 2022. PMID: 35339843 Free article. Review.
A gender-related dichotomy in bladder cancer.
Cimadamore A, Teoh JY, DI Trapani E, Krajewski W, Tan WS, Mori K, Del Giudice F, Carrion DM, Moschini M; European Association of Urology-Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Cimadamore A, et al. Among authors: mori k. Minerva Urol Nephrol. 2022 Jun;74(3):376-378. doi: 10.23736/S2724-6051.22.04954-0. Minerva Urol Nephrol. 2022. PMID: 35607787 Free article. No abstract available.
7,018 results